A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.

IMMX Insider Trading (Immix Biopharma)

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $550.00

Immix Biopharma Insider Trading History Chart

This chart shows the insider buying and selling history at Immix Biopharma by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immix Biopharma Share Price & Price History

Current Price: $2.45
Price Change: Price Decrease of -0.01 (-0.41%)
As of 08/12/2022 01:00 AM ET

This chart shows the closing price history over time for IMMX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!

Immix Biopharma Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/14/2022Sean SennMajor ShareholderSell200$2.75$550.00899,800View SEC Filing Icon  
See Full Table
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.

SEC Filings (Institutional Ownership Changes) for Immix Biopharma (NASDAQ:IMMX)

10.89% of Immix Biopharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IMMX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Immix Biopharma Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/17/2022Virtu Financial LLC23,515$57K0.0%N/A0.170%Search for SEC Filing on Google Icon
5/13/2022Renaissance Technologies LLC62,600$0.15M0.0%N/A0.452%Search for SEC Filing on Google Icon
5/13/2022XTX Topco Ltd12,992$31K0.0%N/A0.094%Search for SEC Filing on Google Icon
5/11/2022InterOcean Capital Group LLC15,900$38K0.0%N/A0.115%Search for SEC Filing on Google Icon
2/14/2022Altium Capital Management LP122,388$0.44M0.1%N/A1.616%Search for SEC Filing on Google Icon
2/14/2022Murchinson Ltd.695,600$2.48M0.2%N/A9.183%Search for SEC Filing on Google Icon
2/9/2022Context Capital Management LLC11,532$41K0.0%N/A0.152%Search for SEC Filing on Google Icon
2/2/2022PVG Asset Management Corp20,000$71K0.3%N/A0.264%Search for SEC Filing on Google Icon
2/1/2022Eidelman Virant Capital29,856$0.10M0.0%N/A0.394%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Immix Biopharma logo
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Read More on Immix Biopharma

Today's Range

Now: $2.45
Low: $2.41
High: $2.49

50 Day Range

MA: $2.50
Low: $2.12
High: $3.05

52 Week Range

Now: $2.45
Low: $1.25
High: $8.68

Volume

24,307 shs

Average Volume

68,698 shs

Market Capitalization

$34.03 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Immix Biopharma?

Immix Biopharma's top insider investors include:
  1. Sean Senn (Major Shareholder)
Learn More about top insider investors at Immix Biopharma.
Inflation Emergency to Disrupt Your Financial Future?
No doubt, we’re in an inflation emergency. It’s driving up prices more quickly than anything we’ve seen in our lifetime. And it’s barely begun.

What impact will this change have on your money?

How can you prepare starting right now?

Watch the emergency briefing from Expert Sean Brodrick.
>>>